Global Pharmaceutical Manufacturing Industry 2020-2027 by Formulation, Route of Administration, Age Group, Therapeutic Application, Drug Type, Distribution Channel, Manufacturing Facility, and Region: Trend Forecast and Growth Opportunity
Market Executive Summary
Global pharmaceutical manufacturing industry will reach $673.6 billion by 2027, growing by 12.5% annually over 2020-2027 driven by increased drug approvals, increasing prevalence of chronic ailments, growing geriatric population, high investment in research and development, and increasing per capita healthcare expenditure amid the COVID-19 pandemic.
Highlighted with 85 tables and 96 figures, this 185-page report ?Global Pharmaceutical Manufacturing Industry 2020-2027 by Formulation, Route of Administration, Age Group, Therapeutic Application, Drug Type, Distribution Channel, Manufacturing Facility, and Region: Trend Forecast and Growth Opportunity? is based on a comprehensive research of the entire global pharmaceutical manufacturing industry and all its sub-segments through extensively detailed classifications. Profound analysis and assessment are generated from premium primary and secondary information sources with inputs derived from industry professionals across the value chain. The report is based on studies on 2017-2019 and provides estimate/forecast from 2020 till 2027 with 2019 as the base year. (Please note: The report will be updated before delivery so that the latest historical year is the base year and the forecast covers at least 5 years over the base year.)
In-depth qualitative analyses include identification and investigation of the following aspects:
? Industry Structure
? Growth Drivers
? Restraints and Challenges
? Emerging Product Trends & Industry Opportunities
? Porter?s Fiver Forces
The trend and outlook of global industry is forecast in optimistic, balanced, and conservative view by taking into account of COVID-19. The balanced (most likely) projection is used to quantify global pharmaceutical manufacturing industry in every aspect of the classification from perspectives of Formulation, Route of Administration, Age Group, Therapeutic Application, Drug Type, Distribution Channel, Manufacturing Facility, and Region.
Based on Formulation, the global industry is segmented into the following sub-markets with annual production value for 2017-2027 included in each section.
? Tablets
? Capsules
? Injectable
? Sprays
? Suspensions
? Powders
? Other Formulations
Based on Route of Administration, the global industry is segmented into the following sub-markets with annual production value for 2017-2027 included in each section.
? Oral Medicine
? Topical Medicine
? Parenteral Medicine
? Inhalations
? Other Routes of Administration
Based on Age Group, the global industry is segmented into the following sub-markets with annual production value for 2017-2027 included in each section.
? Children & Adolescents
? Adults
? Geriatric
Based on Therapeutic Application, the global industry is segmented into the following sub-markets with annual production value for 2017-2027 included in each section.
? Cardiovascular Diseases
? Pain
? Diabetes
? Cancer
? Respiratory Diseases
? Neurological Diseases
? Orthopedics
? Other Applications
Based on Drug Type, the global industry is segmented into the following sub-markets with annual production value for 2017-2027 included in each section.
? Branded Prescription Drugs
? Generic Prescription Drugs
? OTC Drugs
Based on Distribution Channels, the global industry is segmented into the following sub-markets with annual production value for 2017-2027 included in each section.
? Retail Channels
? Non-retail Channels
Based on Manufacturing Facility, the global industry is segmented into the following sub-markets with annual production value for 2017-2027 included in each section.
? In-house Facility
? Outsourced Facility
Geographically, the following regions together with the listed national/local markets are fully investigated:
? APAC (Japan, China, South Korea, Australia, India, and Rest of APAC; Rest of APAC is further segmented into Malaysia, Singapore, Indonesia, Thailand, New Zealand, Vietnam, Taiwan, and Philippines)
? Europe (Germany, UK, France, Spain, Italy, Russia, Rest of Europe; Rest of Europe is further segmented into Netherlands, Switzerland, Turkey, Poland, Sweden, Belgium, Austria, Ireland, Norway, Denmark, and Finland)
? North America (U.S., Canada, and Mexico)
? South America (Brazil, Chile, Argentina, Rest of South America)
? MEA (UAE, Saudi Arabia, South Africa)
For each aforementioned region and country, detailed analysis and data for annual production value are available for 2017-2027. The breakdown of all regional markets by country and split of key national industry by Formulation, Route of Administration, and Drug Type over the forecast years are also included.
The report also covers current competitive scenario and the predicted trend; and profiles key vendors including industry leaders and important emerging players.
Specifically, potential risks associated with investing in global pharmaceutical manufacturing industry are assayed quantitatively and qualitatively through GMD?s Risk Assessment System. According to the risk analysis and evaluation, Critical Success Factors (CSFs) are generated as a guidance to help investors & stockholders identify emerging opportunities, manage and minimize the risks, develop appropriate business models, and make wise strategies and decisions.
Key Players (this may not be a complete list and extra companies can be added upon request):
Abbott Laboratories
Aenova Group
Amgen
AstraZeneca
Catalent Inc.
Eli Lilly and Company
F. Hoffmann-La Roche Ltd.
Gilead Sciences
GlaxoSmithKline plc
Johnson & Johnson
Lonza Group
Lupin
Merck & Co., Inc.
Novartis AG
Novo Nordisk
Pfizer, Inc.
Roche
Sanofi SA
Takeda
(Please note: The report will be updated before delivery so that the latest historical year is the base year and the forecast covers at least 5 years over the base year.)
Table of Contents
Table of Contents
1 Introduction 10
1.1 Industry Definition and Research Scope 10
1.1.1 Industry Definition 10
1.1.2 Research Scope 11
1.2 Research Methodology 14
1.2.1 Overview of Industry Research Methodology 14
1.2.2 Industry Assumption 15
1.2.3 Secondary Data 15
1.2.4 Primary Data 15
1.2.5 Data Filtration and Model Design 17
1.2.6 Industry Size/Share Estimation 18
1.2.7 Research Limitations 19
1.3 Executive Summary 20
2 Industry Overview and Dynamics 23
2.1 Industry Size and Forecast 23
2.1.1 Impact of COVID-19 on World Economy 24
2.1.2 Impact of COVID-19 on the Industry 27
2.2 Major Growth Drivers 29
2.3 Industry Restraints and Challenges 32
2.4 Emerging Opportunities and Industry Trends 35
2.5 Porter?s Fiver Forces Analysis 39
3 Segmentation of Global Industry by Formulation 43
3.1 Industry Overview by Formulation 43
3.2 Tablets 45
3.3 Capsules 46
3.4 Injectable 47
3.5 Sprays 48
3.6 Suspensions 49
3.7 Powders 50
3.8 Other Formulations 51
4 Segmentation of Global Industry by Route of Administration 52
4.1 Industry Overview by Route of Administration 52
4.2 Oral Medicine 54
4.3 Topical Medicine 55
4.4 Parenteral Medicine 56
4.5 Inhalations 57
4.6 Other Routes of Administration 58
5 Segmentation of Global Industry by Age Group 59
5.1 Industry Overview by Age Group 59
5.2 Children & Adolescents 61
5.3 Adults 62
5.4 Geriatric 63
6 Segmentation of Global Industry by Therapeutic Application 64
6.1 Industry Overview by Therapeutic Application 64
6.2 Cardiovascular Diseases 66
6.3 Pain 67
6.4 Diabetes 68
6.5 Cancer 69
6.6 Respiratory Diseases 70
6.7 Neurological Diseases 71
6.8 Orthopedics 72
6.9 Other Applications 73
7 Segmentation of Global Industry by Drug Type 74
7.1 Industry Overview by Drug Type 74
7.2 Branded Prescription Drugs 76
7.3 Generic Prescription Drugs 77
7.4 OTC Drugs 78
8 Segmentation of Global Industry by Distribution Channels 79
8.1 Industry Overview by Distribution Channels 79
8.2 Retail Channels 81
8.3 Non-retail Channels 82
9 Segmentation of Global Industry by Manufacturing Facility 83
9.1 Industry Overview by Manufacturing Facility 83
9.2 In-house Facility 85
9.3 Outsourced Facility 86
10 Segmentation of Global Industry by Region 87
10.1 Geographic Industry Overview 2020-2027 87
10.2 North America Industry 2020-2027 by Country 91
10.2.1 Overview of North America Industry 91
10.2.2 U.S. 94
10.2.3 Canada 98
10.2.4 Mexico 100
10.3 European Industry 2020-2027 by Country 102
10.3.1 Overview of European Industry 102
10.3.2 UK 105
10.3.3 France 107
10.3.4 Germany 109
10.3.5 Spain 111
10.3.6 Italy 113
10.3.7 Russia 115
10.3.8 Rest of European Industry 117
10.4 Asia-Pacific Industry 2020-2027 by Country 119
10.4.1 Overview of Asia-Pacific Industry 119
10.4.2 China 122
10.4.3 Japan 124
10.4.4 India 127
10.4.5 Australia 129
10.4.6 South Korea 131
10.4.7 Rest of APAC Region 133
10.5 South America Industry 2020-2027 by Country 135
10.5.1 Argentina 138
10.5.2 Brazil 140
10.5.3 Chile 142
10.5.4 Rest of South America Industry 144
10.6 MEA Industry 2020-2027 by Country 145
10.6.1 UAE 148
10.6.2 Saudi Arabia 150
10.6.3 South Africa 152
10.6.4 Other National Markets 154
11 Competitive Landscape 155
11.1 Overview of Key Vendors 155
11.2 New Product Launch, Partnership, Investment, and M&A 158
11.3 Company Profiles 159
Abbott Laboratories 159
Aenova Group 161
Amgen 162
AstraZeneca 163
Catalent Inc. 164
Eli Lilly and Company 165
F. Hoffmann-La Roche Ltd. 166
Gilead Sciences 167
GlaxoSmithKline plc 168
Johnson & Johnson 169
Lonza Group 170
Lupin 171
Merck & Co., Inc. 172
Novartis AG 173
Novo Nordisk 174
Pfizer, Inc. 175
Roche 176
Sanofi SA 177
Takeda 178
12 Investing in Global Industry: Risk Assessment and Management 179
12.1 Risk Evaluation of Global Industry 179
12.2 Critical Success Factors (CSFs) 182
Related Reports and Products 185
List of Figures
Figure 1. Research Method Flow Chart 14
Figure 2. Breakdown of Primary Research 16
Figure 3. Bottom-up Approach and Top-down Approach for Industry Estimation 18
Figure 4. Global Industry Forecast in Optimistic, Conservative and Balanced Perspectives, 2020-2027 20
Figure 5. Global Pharmaceutical Manufacturing Industry, 2017-2027, $ bn 23
Figure 6. Impact of COVID-19 on Business 27
Figure 7. Primary Drivers and Impact Factors of Global Pharmaceutical Manufacturing Industry 29
Figure 8. Primary Restraints and Impact Factors of Global Pharmaceutical Manufacturing Industry 32
Figure 9. Investment Opportunity Analysis 36
Figure 10. Porter?s Fiver Forces Analysis of Global Pharmaceutical Manufacturing Industry 39
Figure 11. Breakdown of Global Pharmaceutical Manufacturing Industry by Formulation, 2020-2027, % of Revenue 44
Figure 12. Contribution to Global 2021-2027 Cumulative Revenue by Formulation, Value ($ bn) and Share (%) 44
Figure 13. Global Pharmaceutical Manufacturing Industry: Tablets, 2017-2027, $ bn 45
Figure 14. Global Pharmaceutical Manufacturing Industry: Capsules, 2017-2027, $ bn 46
Figure 15. Global Pharmaceutical Manufacturing Industry: Injectable, 2017-2027, $ bn 47
Figure 16. Global Pharmaceutical Manufacturing Industry: Sprays, 2017-2027, $ bn 48
Figure 17. Global Pharmaceutical Manufacturing Industry: Suspensions, 2017-2027, $ bn 49
Figure 18. Global Pharmaceutical Manufacturing Industry: Powders, 2017-2027, $ bn 50
Figure 19. Global Pharmaceutical Manufacturing Industry: Other Formulations, 2017-2027, $ bn 51
Figure 20. Breakdown of Global Pharmaceutical Manufacturing Industry by Route of Administration, 2020-2027, % of Revenue 53
Figure 21. Contribution to Global 2021-2027 Cumulative Revenue by Route of Administration, Value ($ bn) and Share (%) 53
Figure 22. Global Pharmaceutical Manufacturing Industry: Oral Medicine, 2017-2027, $ bn 54
Figure 23. Global Pharmaceutical Manufacturing Industry: Topical Medicine, 2017-2027, $ bn 55
Figure 24. Global Pharmaceutical Manufacturing Industry: Parenteral Medicine, 2017-2027, $ bn 56
Figure 25. Global Pharmaceutical Manufacturing Industry: Inhalations, 2017-2027, $ bn 57
Figure 26. Global Pharmaceutical Manufacturing Industry: Other Routes of Administration, 2017-2027, $ bn 58
Figure 27. Breakdown of Global Pharmaceutical Manufacturing Industry by Age Group, 2020-2027, % of Revenue 59
Figure 28. Contribution to Global 2021-2027 Cumulative Revenue by Age Group, Value ($ bn) and Share (%) 60
Figure 29. Global Pharmaceutical Manufacturing Industry: Children & Adolescents, 2017-2027, $ bn 61
Figure 30. Global Pharmaceutical Manufacturing Industry: Adults, 2017-2027, $ bn 62
Figure 31. Global Pharmaceutical Manufacturing Industry: Geriatric, 2017-2027, $ bn 63
Figure 32. Breakdown of Global Pharmaceutical Manufacturing Industry by Therapeutic Application, 2020-2027, % of Revenue 65
Figure 33. Contribution to Global 2021-2027 Cumulative Revenue by Therapeutic Application, Value ($ bn) and Share (%) 65
Figure 34. Global Pharmaceutical Manufacturing Industry: Cardiovascular Diseases, 2017-2027, $ bn 66
Figure 35. Global Pharmaceutical Manufacturing Industry: Pain, 2017-2027, $ bn 67
Figure 36. Global Pharmaceutical Manufacturing Industry: Diabetes, 2017-2027, $ bn 68
Figure 37. Global Pharmaceutical Manufacturing Industry: Cancer, 2017-2027, $ bn 69
Figure 38. Global Pharmaceutical Manufacturing Industry: Respiratory Diseases, 2017-2027, $ bn 70
Figure 39. Global Pharmaceutical Manufacturing Industry: Neurological Diseases, 2017-2027, $ bn 71
Figure 40. Global Pharmaceutical Manufacturing Industry: Orthopedics, 2017-2027, $ bn 72
Figure 41. Global Pharmaceutical Manufacturing Industry: Other Applications, 2017-2027, $ bn 73
Figure 42. Breakdown of Global Pharmaceutical Manufacturing Industry by Drug Type, 2020-2027, % of Revenue 74
Figure 43. Contribution to Global 2021-2027 Cumulative Revenue by Drug Type, Value ($ bn) and Share (%) 75
Figure 44. Global Pharmaceutical Manufacturing Industry: Branded Prescription Drugs, 2017-2027, $ bn 76
Figure 45. Global Pharmaceutical Manufacturing Industry: Generic Prescription Drugs, 2017-2027, $ bn 77
Figure 46. Global Pharmaceutical Manufacturing Industry: OTC Drugs, 2017-2027, $ bn 78
Figure 47. Breakdown of Global Pharmaceutical Manufacturing Industry by Distribution Channels, 2020-2027, % of Revenue 79
Figure 48. Contribution to Global 2021-2027 Cumulative Revenue by Distribution Channels, Value ($ bn) and Share (%) 80
Figure 49. Global Pharmaceutical Manufacturing Industry: Retail Channels, 2017-2027, $ bn 81
Figure 50. Global Pharmaceutical Manufacturing Industry: Non-retail Channels, 2017-2027, $ bn 82
Figure 51. Breakdown of Global Pharmaceutical Manufacturing Industry by Manufacturing Facility, 2020-2027, % of Revenue 84
Figure 52. Contribution to Global 2021-2027 Cumulative Revenue by Manufacturing Facility, Value ($ bn) and Share (%) 84
Figure 53. Global Pharmaceutical Manufacturing Industry: In-house Facility, 2017-2027, $ bn 85
Figure 54. Global Pharmaceutical Manufacturing Industry: Outsourced Facility, 2017-2027, $ bn 86
Figure 55. Global Industry Snapshot by Region 87
Figure 56. Geographic Spread of Worldwide Pharmaceutical Manufacturing Industry, 2020-2027, % of Revenue 88
Figure 57. Contribution to Global 2021-2027 Cumulative Revenue by Region, Value ($ bn) and Share (%) 89
Figure 58. North American Pharmaceutical Manufacturing Industry, 2017-2027, $ bn 92
Figure 59. Breakdown of North America Pharmaceutical Manufacturing Industry by Country, 2020 and 2027, % of Revenue 92
Figure 60. Contribution to North America 2021-2027 Cumulative Revenue by Country, Value ($ bn) and Share (%) 93
Figure 61. U.S. Pharmaceutical Manufacturing Industry, 2017-2027, $ bn 95
Figure 62. Canada Pharmaceutical Manufacturing Industry, 2017-2027, $ bn 98
Figure 63. Pharmaceutical Manufacturing Industry in Mexico, 2017-2027, $ bn 100
Figure 64. European Pharmaceutical Manufacturing Industry, 2017-2027, $ bn 103
Figure 65. Breakdown of European Pharmaceutical Manufacturing Industry by Country, 2020 and 2027, % of Revenue 103
Figure 66. Contribution to Europe 2021-2027 Cumulative Revenue by Country, Value ($ bn) and Share (%) 104
Figure 67. Pharmaceutical Manufacturing Industry in UK, 2017-2027, $ bn 105
Figure 68. Pharmaceutical Manufacturing Industry in France, 2017-2027, $ bn 107
Figure 69. Pharmaceutical Manufacturing Industry in Germany, 2017-2027, $ bn 109
Figure 70. Pharmaceutical Manufacturing Industry in Spain, 2017-2027, $ bn 111
Figure 71. Pharmaceutical Manufacturing Industry in Italy, 2017-2027, $ bn 113
Figure 72. Pharmaceutical Manufacturing Industry in Russia, 2017-2027, $ bn 115
Figure 73. Pharmaceutical Manufacturing Industry in Rest of Europe, 2017-2027, $ bn 117
Figure 74. Asia-Pacific Pharmaceutical Manufacturing Industry, 2017-2027, $ bn 120
Figure 75. Breakdown of APAC Pharmaceutical Manufacturing Industry by Country, 2020 and 2027, % of Revenue 120
Figure 76. Contribution to APAC 2021-2027 Cumulative Revenue by Country, Value ($ bn) and Share (%) 121
Figure 77. Pharmaceutical Manufacturing Industry in China, 2017-2027, $ bn 122
Figure 78. Pharmaceutical Manufacturing Industry in Japan, 2017-2027, $ bn 125
Figure 79. Pharmaceutical Manufacturing Industry in India, 2017-2027, $ bn 127
Figure 80. Pharmaceutical Manufacturing Industry in Australia, 2017-2027, $ bn 129
Figure 81. Pharmaceutical Manufacturing Industry in South Korea, 2017-2027, $ bn 131
Figure 82. Pharmaceutical Manufacturing Industry in Rest of APAC, 2017-2027, $ bn 133
Figure 83. South America Pharmaceutical Manufacturing Industry, 2017-2027, $ bn 136
Figure 84. Breakdown of South America Pharmaceutical Manufacturing Industry by Country, 2020 and 2027, % of Revenue 136
Figure 85. Contribution to South America 2021-2027 Cumulative Revenue by Country, Value ($ bn) and Share (%) 137
Figure 86. Pharmaceutical Manufacturing Industry in Argentina, 2017-2027, $ bn 138
Figure 87. Pharmaceutical Manufacturing Industry in Brazil, 2017-2027, $ bn 140
Figure 88. Pharmaceutical Manufacturing Industry in Chile, 2017-2027, $ bn 142
Figure 89. Pharmaceutical Manufacturing Industry in Rest of South America, 2017-2027, $ bn 144
Figure 90. Pharmaceutical Manufacturing Industry in Middle East and Africa (MEA), 2017-2027, $ bn 146
Figure 91. Breakdown of MEA Pharmaceutical Manufacturing Industry by Country, 2020 and 2027, % of Revenue 146
Figure 92. Contribution to MEA 2021-2027 Cumulative Revenue by Country, Value ($ bn) and Share (%) 147
Figure 93. Pharmaceutical Manufacturing Industry in UAE, 2017-2027, $ bn 148
Figure 94. Pharmaceutical Manufacturing Industry in Saudi Arabia, 2017-2027, $ bn 150
Figure 95. Pharmaceutical Manufacturing Industry in South Africa, 2017-2027, $ bn 152
Figure 96. Growth Stage of Global Industrial Robot Software Industry over the Forecast Period 155
This report focuses on:
► Intelligent insights to take informed business decisions.
► Qualitative and quantitative analysis of the market.
► Market size and forecasts from 2024 to 2030.
► Opportunities for expansion and in-depth market analysis.
► Segmentation and regional revenue forecasts.
► Analysis of the market share and competitive landscape.
► Strategic recommendations for future growth.
You'll also receive:
► A comprehensive market research report in PDF or PPT formats.
► Access to our analysts to learn more about the report and get answers to your specific business questions.
► The option to customize the report to meet your specific needs, such as adding more countries or regions or developing abusiness case to launch a new product.
Contact us today to learn more and get sample report.
Our Research Reports Look Like This
